Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Ordinary shares, par value $0.0135 per share
-
Shares outstanding
-
2.26M
-
Number of holders
-
6
-
Total 13F shares, excl. options
-
282K
-
Shares change
-
+45.5K
-
Total reported value, excl. options
-
$229K
-
Value change
-
+$32.5K
-
Number of buys
-
3
-
Number of sells
-
-1
-
Price
-
$0.81
Significant Holders of Silexion Therapeutics Corp - Ordinary shares, par value $0.0135 per share (SLXN) as of Q2 2025
7 filings reported holding SLXN - Silexion Therapeutics Corp - Ordinary shares, par value $0.0135 per share as of Q2 2025.
Silexion Therapeutics Corp - Ordinary shares, par value $0.0135 per share (SLXN) has 6 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 282K shares
of 2.26M outstanding shares and own 12.45% of the company stock.
Largest 7 shareholders include Wildcat Capital Management, LLC (113K shares), UBS Group AG (109K shares), MEYER HANDELMAN CO (33K shares), Virtu Financial LLC (14.3K shares), StoneX Group Inc. (11.2K shares), BANK OF AMERICA CORP /DE/ (500 shares), and SBI Securities Co., Ltd. (0 shares).
This table shows the top 6 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.